CRDL
CRDL clinical trials: Cardiol Therapeutics Inc.
Every trial on ClinicalTrials.gov where Cardiol Therapeutics Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 4
- Trials linked
- 4
- As lead sponsor
- 0
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
CRDL on the catalyst calendar · CRDL registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Sep 21, 2026Sponsor estimate | NCT06708299CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)Cardiol Therapeutics Inc. · Recurrent Pericarditis | CRDLLead | Phase 3 | Recruiting | Locked | Locked | Locked |
| Jan 31, 2025Actual | NCT05180240Impact of CardiolRx on Myocardial Recovery in Patients With Acute MyocarditisCardiol Therapeutics Inc. · Acute Myocarditis | CRDLLead | Phase 2 | Completed | Locked | Locked | Locked |
| Nov 30, 2022Actual | NCT04615949Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsCardiol Therapeutics Inc. · COVID-19 | CRDLLead | Phase 2/Phase 3 | Terminated | Locked | Locked | Locked |
| Jun 15, 2024Actual | NCT05494788Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)Cardiol Therapeutics Inc. · Recurrent Pericarditis | CRDLLead | Phase 2 | Completed | Locked | Locked | Locked |
- Primary completion Sep 21, 2026Sponsor estimatePhase 3NCT06708299CardiolRx in Recurrent Pericarditis (MAVERIC Phase-3)Cardiol Therapeutics Inc. · Recurrent PericarditisRecruitingCRDLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jan 31, 2025ActualPhase 2NCT05180240Impact of CardiolRx on Myocardial Recovery in Patients With Acute MyocarditisCardiol Therapeutics Inc. · Acute MyocarditisCompletedCRDLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Nov 30, 2022ActualPhase 2/Phase 3NCT04615949Cannabidiol in Patients With COVID-19 and Cardiovascular Disease or Risk FactorsCardiol Therapeutics Inc. · COVID-19TerminatedCRDLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 15, 2024ActualPhase 2NCT05494788Impact of CardiolRxTM on Recurrent Pericarditis (MAvERIC-Pilot)Cardiol Therapeutics Inc. · Recurrent PericarditisCompletedCRDLLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 4 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner